Search | Clinical Trials Finder

Conditions: Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 15
States / cities: Birmingham, Alabama • Glendale, California • San Francisco, California + 10 more

Conditions: Pancreatic Cancer
Interventions: Canakinumab, Tislelizumab, Nab-Paclitaxel, Gemcitabine; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: New York, New York

Conditions: Polymyalgia Rheumatica, Inflammatory Diseases
Interventions: AIN457, ACZ885, Prednisone, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Atherosclerosis
Interventions: Canakinumab, Placebo, Standard of care; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 10,066 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 315
States / cities: Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 248 more

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine; Drug
Lead sponsor: Pancreatic Cancer Action Network; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Rheumatoid Arthritis
Interventions: Canakinumab; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 20
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 17 more

Conditions: Fibrodysplasia Ossificans Progressiva (FOP)
Interventions: Anti-IL1 Therapy; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 6 Years to 30 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Vascular Inflammation, ASCVD, ASCVD Management
Interventions: CANAKINUMAB (ILARIS®), Saline (NaCl 0,9 %) (placebo); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gouty Arthritis
Interventions: Canakinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Triple Negative Breast Cancer (TNBC)
Interventions: spartalizumab, LAG525, NIR178, capmatinib, MCS110, canakinumab; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: New York, New York • Nashville, Tennessee

Conditions: Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Interventions: PDR001, ACZ885, CJM112, TMT212, EGF816; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: Gout
Interventions: Canakinumab, Colchicine, Allopurinol, Placebo Matching Canakinumab, Placebo Matching Colchicine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 19
States / cities: Huntington Beach, California • San Diego, California • Jupiter, Florida + 16 more

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Interventions: Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab; Drug
Lead sponsor: Jeffrey Curtis; Other
Eligibility: 18 Years to 85 Years
Enrollment: 841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more

Conditions: Rheumatoid Arthritis
Interventions: Canakinumab (investigational), Placebo, Methotrexate (MTX); Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 14 more

Conditions: Hereditary Periodic Fevers
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Month and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Los Angeles, California • Ann Arbor, Michigan • Cleveland, Ohio

Conditions: Muckle Wells Syndrome
Interventions: ACZ885, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 4 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Madison, Wisconsin

Conditions: Clonal Cytopenia of Undetermined Significance
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Canakinumab, Chest Radiography, Echocardiography, Placebo Administration, Quality-of-Life Assessment; Procedure · Drug · Other
Lead sponsor: Uma Borate; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Miami, Florida • New York, New York • Columbus, Ohio + 2 more

Conditions: Knee Osteoarthritis
Interventions: canakinumab, LNA043, Placebo to canakinumab; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: La Mesa, California • Clearwater, Florida • Sunrise, Florida + 2 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Canakinumab Injection [Ilaris]; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 2 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Systemic Juvenile Idiopathic Arthritis
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 19 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 15
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more

Conditions: Diabetes Mellitus, Type 2, Atherosclerosis, Prediabetic State
Interventions: ACZ885, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: New York, New York • Cincinnati, Ohio

Conditions: Non-Small Cell Lung Cancer
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 21
States / cities: Fayetteville, Arkansas • Los Alamitos, California • Los Angeles, California + 18 more

Conditions: COVID-19, SARS-CoV 2
Interventions: Canakinumab Injection 600mg, Canakinumab Injection 300mg, Placebos; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Weston, Florida • Cleveland, Ohio

Conditions: Non-small Cell Lung Cancer
Interventions: canakinumab, canakinumab-matching placebo, pembrolizumab, carboplatin, cisplatin, paclitaxel, nab-paclitaxel, pemetrexed; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 4
States / cities: Long Beach, California • Los Angeles, California • Orlando, Florida + 1 more

Search by objective public record fields.

Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients

Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis

IL1 Inhibition in FOP

Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

Long Term Study of Canakinumab (ACZ885) in Patients With Gout

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

COVID-19 VaccinE Response in Rheumatology Patients

Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)

Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

Canakinumab in Covid-19 Cardiac Injury (The Three C Study)

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects